Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said ImmunityBio, Inc. (NASDAQ:IBRX) is a “very good spec.”

ImmunityBio, on Oct. 14, announced that the FDA expanded the approved indication for its bladder cancer immunotherapy ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors.

Cramer recommended sticking with Monster Beverage Corporation (NASDAQ:MNST) when asked about Celsius Holdings, Inc. (NASDAQ:CELH). “We know Celsius is a second-rate Monster,” he added.

JPMorgan analyst Andrea Teixeira maintained an Overweight rating on Celsius on Monday and lowered the price target from $52 to $48.

Cramer advised against touching USA Rare Earth, Inc. (NASDAQ:USAR).

On earnings, USA Rare Earth reported worse-than-expected second-quarter results on Aug. 10.

The Mad Money host said he likes Glacier Bancorp, Inc. (NYSE:GBCI). “Now the stock just had a very big move. It’s at $49, but that stock could retrace to $45 without a problem. But it does have good growth. It has a decent yield, and most importantly, it’s in a growth area of the country, which is exactly what you need,” he added.

Supporting his choice, Glacier Bancorp reported quarterly earnings of 81 cents per share on Oct. 22, beating the analyst consensus estimate of 79 cents per share. The company reported quarterly sales of $329.84 million, which beat the analyst consensus estimate of $290.69 million.

Price Action:

• Celsius shares fell 1.1% to settle at $28.15 on Monday.
• USA Rare Earth shares declined 4.5% to close at $8.91 during the session.
• Glacier Bancorp gained 2.5% to settle at $49.00 on Monday.
• ImmunityBio shares dipped 5% to close at $7.81 during the session.

Photo via Shutterstock